COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Intermittent Pneumatic Compression of the Foot vs Geko Plus R-2 Neuromuscular Electrostimulation Device in Venous Leg Ulcer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02912858
Recruitment Status : Withdrawn (study withdrawn)
First Posted : September 23, 2016
Last Update Posted : February 7, 2018
Information provided by (Responsible Party):
Firstkind Ltd

Brief Summary:
Chronic venous leg ulcers (VLU) are painful, debilitating wounds that place a significant burden on the patient, their family, and healthcare resources. Treating VLU can present a significant challenge to clinicians, who currently have a limited range of treatments at their disposal. The mainstay of treatment is compression bandaging, ambulation and elevation at rest. In addition to the aforementioned, intermittent pneumatic compression has also been utilised1. When applied to the leg or foot intermittent pneumatic compression (IPC) devices intermittently inflate and deflate to increase venous return. These devices can be uncomfortable to wear, and compliance can be inhibited because of size, weight and external power source that limit the patient's mobility. In patients who cannot walk, or in those who are unable to tolerate compression bandaging, ulcers may deteriorate and never heal. Accordingly, there is a need for novel, alternative devices or strategies that can be used to complement or replace compression bandage therapy.

Condition or disease Intervention/treatment Phase
Venous Leg Ulcer Device: geko plus R-2 Not Applicable

Detailed Description:

This is a single-centre randomised intra-patient comparison of gekoTM plus R-2 R-2 and IPC.

Blood flow will be measured after each device has been activated for 10 minutes with a 10 minute rest between devices to allow blood flow to return to baseline. The order the devices will be fitted is determined randomly. Activation of the device for 10 minutes before measurement is deemed appropriate as previous studies have demonstrated significant increases in blood flow following as little as five minutes use of the devices.

In this short study the standard of care (typically compression bandaging), will be suspended temporarily to allow the fitting of the gekoTM plus R-2 and IPC devices in order to measure blood flow. This is not seen as a risk to the patient as the device is only in operation for 30 minutes plus 10 minutes rest within the care pathway.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Intermittent Pneumatic Compression of the Foot vs Geko Plus R-2 Neuromuscular Electrostimulation Device in Venous Leg Ulcer Patients: Comparison of Effects on Lower Limb Circulation
Estimated Study Start Date : September 2017
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: geko plus R-2
neuromuscular electrostimulation
Device: geko plus R-2

The gekoTM plus R-2 devices (acting on the common peroneal nerve) and IPC devices will be activated for 10mins prior to measuring blood flow.

The sequence of application of IPC and gekoTM plus R-2 devices will be randomly selected with 10 minutes recovery between active therapies.

Primary Outcome Measures :
  1. The lower limb blood flow between gekoTM plus R-2 and IPC devices in VLU patients will be assessed. [ Time Frame: 3 months ]
    Duplex ultrasound of the femoral vein and artery will be performed with bilateral recording of blood flow velocity. After 10 minutes activation of either geko™ or IPC and after the 10 minutes the devices will swapped over and measurements performed. All measurements to be carried out in triplicate.

Secondary Outcome Measures :
  1. Adverse events assessments [ Time Frame: 3 months ]

    Patients will be monitored for adverse events throughout the duration of the study. Adverse events may be spontaneously reported by the subject, observed by the study personnel.

    Serious Adverse Events will be reported to the Sponsor, the National Research Ethics Service (NRES) recognised Research Ethics Committee.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Intact healthy skin at the site of device application
  3. Able to understand the Patient Information Sheet
  4. Willing and able to give informed consent
  5. Willing and able to follow the requirements of the protocol
  6. Subjects who had a chronic venous leg ulcer (i.e. CEAP classification of C6 1) greater than 2 cm2 and less than 10 cm in maximum diameter,
  7. ABPI of 0.8-1.2 inclusive

Exclusion Criteria:

  1. Wound infection either acute or chronic
  2. History of significant haematological disorders or DVT with the preceding six months
  3. Pregnant
  4. Pacemakers or implantable defibrillators
  5. Use of any other neuro-modulation device
  6. Current use of TENS in pelvic region, back or legs
  7. Use of investigational drug or device within the past 4 weeks that may interfere with this study
  8. Recent surgery that may affect the study (such as abdominopelvic, or lower limb) in the opinion of the investigator.
  9. Recent trauma to the lower limbs
  10. Size of leg incompatible with the gekoTM plus R-2 device
  11. Obesity (BMI > 34)
  12. Any medication deemed to be significant by the Investigator
  13. Subjects who had an index venous leg ulcer greater in maximum diameter than 10cm in any one dimension, or less than 2cm.
  14. Diabetes
  15. Clinical evidence of peripheral arterial disease (i.e signs or symptoms, in the opinion of the researcher)
Layout table for additonal information
Responsible Party: Firstkind Ltd Identifier: NCT02912858    
Other Study ID Numbers: FKD-IPC-003
First Posted: September 23, 2016    Key Record Dates
Last Update Posted: February 7, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Varicose Ulcer
Leg Ulcer
Pathologic Processes
Skin Ulcer
Skin Diseases
Varicose Veins
Vascular Diseases
Cardiovascular Diseases